Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117585 | 0.84 | CYP2D6 (0.50) | CYP2C19CYP2D6 | |
| Bicarbonate SCHEMBL11768566 | 0.73 | GRIK1 (0.32) | CYP2C19GRIK1GRIK2CPA1 | |
| SCHEMBL3857558 | 0.72 | — | — | |
| SCHEMBL7002068 | 0.72 | CYP2D6 (0.42) | CYP2C19CYP2D6GRIK1GRIK2TSHR | |
| SCHEMBL5677966 | 0.70 | ABCC4 (0.47) | CYP2C19CYP2D6TSHR | |
| SCHEMBL4148404 | 0.69 | CTSC (0.35) | CYP2C19GRIK1GRIK2CPA1 | |
| SCHEMBL14110494 | 0.69 | CYP2D6 (0.48) | CYP2C19CYP2D6 | |
| SCHEMBL19548743 | 0.68 | GRIK1 (0.39) | CYP2C19CYP2D6GRIK1GRIK2TSHR | |
| SCHEMBL19552436 | 0.68 | GRIK1 (0.39) | CYP2C19CYP2D6GRIK1GRIK2TSHR | |
| SCHEMBL2307423 | 0.68 | CYP2D6 (0.44) | CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099168-A1 | HIV Integrase inhibitors | DONGHI MONICA | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099168-A1 | HIV Integrase inhibitors | DPYD, DUT, QDPR | CYP2C19 815/4885CYP2D6 341/4885GRIK1 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.